Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma

Francine Foss*, Barbara Pro, H. Miles Prince, Lubomir Sokol, Dolores Caballero, Steven Horwitz, Bertrand Coiffier

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalCancer medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • HDAC inhibitor
  • peripheral T-cell lymphoma
  • refractory
  • romidepsin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this